Pfizer announced the death of a patient who was receiving treatment with the drug “Hemphavzy” for hemophilia as part of a long-term study, after experiencing serious side effects.
A patient support group stated that the patient died on December 14 after suffering a stroke.
The patient was enrolled in a study testing the drug “” on patients with hemophilia of either type A or B, with or without inhibitors.
The company said in a statement: “We are actively working with the party responsible for investigating the trial and the independent external data monitoring committee to gather information to better understand the complex, multifactorial circumstances surrounding this incident.”
Last year, the treatment, which is administered via a once-weekly injection, received approval to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia of either type A or B by targeting blood clotting proteins.
The company said it does not anticipate any impact on the safety of patients treated with the drug, based on its current knowledge and the overall clinical data collected to date.
